<!--
Homepage version latest-updates

Instruction:

1. Always use three hashtags (###) to start a section title.

2. Please include an anchor link to the detailed latest updates page in each section title.
   You can click the üîó symbol on detailed latest updates page to find out the corresponding anchor link.
   Please follow the existing sections for the correct format.

3. One paragraph description for each section. The paragraph should contain less than ~200 chars.

4. Dated updates should be listed in descending order.

5. For links from covdb.stanford.edu, please remove the leading "https://covdb.stanford.edu".
   For example, "https://covdb.stanford.edu/page/updates/" should be shorten to "/page/updates/".

6. Try not to include plain links such as [https://stanford.cloud-cme.com/default.aspx?P=0&EID=38044](https://stanford.cloud-cme.com/default.aspx?P=0&EID=38044).
   Please include readable content in the bracket, e.g. [video](https://stanford.cloud-cme.com/default.aspx?P=0&EID=38044).

7. Please do not delete this instruction.

-->
### Database Entries (Apr 11)
Maisonnasse P, Aldon Y, et int., and Grand RL. [‚ÄúCOVA1-18 neutralizing antibody protects against SARS-CoV-2 in three preclinical models.‚Äù](/search/?article=Maisonnasse21) _Research Square_, 2021. [doi.org/10.21203/rs.3.rs-235272/v1](https://doi.org/10.21203/rs.3.rs-235272/v1). \[[PubMed33619476](https://www.ncbi.nlm.nih.gov/pubmed/33619476/)\] \[[PMC7899470](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7899470/)\]
### Database Entries (Apr 11)
Suryadevara N, Shrihari S, et int., and Crowe JE. [‚ÄúNeutralizing and protective human monoclonal antibodies recognizing the N-terminal domain of the SARS-CoV-2 spike protein.‚Äù](/search/?article=Suryadevara21) _Cell_, 2021. [doi.org/10.1016/j.cell.2021.03.029](https://doi.org/10.1016/j.cell.2021.03.029). \[[PubMed33773105](https://www.ncbi.nlm.nih.gov/pubmed/33773105/)\] \[[PMC7962591](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7962591/)\]

### Database Entries (Apr 11)
Wettstein L, Weil T, et int., and M√ºnch J. [‚ÄúAlpha-1 antitrypsin inhibits TMPRSS2 protease activity and SARS-CoV-2 infection.‚Äù](/search/?article=Wettstein21) _Nature Communications_, 2021. [doi.org/10.1038/s41467-021-21972-0](https://doi.org/10.1038/s41467-021-21972-0). \[[PubMed33741941](https://www.ncbi.nlm.nih.gov/pubmed/33741941/)\]
### [Clinical Trials (Apr 08)](/page/updates/#clinical.trials)
[7 clinical trials from ClinicalTrials.gov and WHO ICTRP were added to the registry of Ongoing and Planned Clinical Trials of Antiviral Compounds.](/clinical-trials/?fromDate=2021-04-08)

### Database Entries (Apr 06)
McCallum M, Bassi J, et int., and Veesler D. [‚ÄúSARS-CoV-2 immune evasion by variant B.1.427/B.1.429.‚Äù](/search/?article=McCallum21b) _bioRxiv_, 2021. [doi.org/10.1101/2021.03.31.437925](https://doi.org/10.1101/2021.03.31.437925).
### Database Entries (Apr 06)
de Oliveira T, Lutucuta S, et int., and Lessells RJ. [‚ÄúA novel variant of interest of SARS-CoV-2 with multiple spike mutations is identified from travel surveillance in Africa.‚Äù](/search/?article=Oliviera21) _medRxiv_, 2021. [doi.org/10.1101/2021.03.30.21254323](https://doi.org/10.1101/2021.03.30.21254323).
### Database Entries (Apr 06)
Pandit A, Bhalani N, et int., and Kansagra K. [‚ÄúEfficacy and safety of pegylated interferon alfa-2b in moderate COVID-19: A phase II, randomized, controlled, open-label study.‚Äù](/search/?article=Pandit21) _International Journal of Infectious Diseases_, 2021. [doi.org/10.1016/j.ijid.2021.03.015](https://doi.org/10.1016/j.ijid.2021.03.015). \[[PubMed33713817](https://www.ncbi.nlm.nih.gov/pubmed/33713817/)\] \[[PMC7944859](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7944859/)\]
### Database Entries (Apr 06)
Tegally H, Wilkinson E, et int., and de Oliveira T. [‚ÄúDetection of a SARS-CoV-2 variant of concern in South Africa.‚Äù](/search/?article=Tegally21) _Nature_, 2021. [doi.org/10.1038/s41586-021-03402-9](https://doi.org/10.1038/s41586-021-03402-9). \[[PubMed33690265](https://www.ncbi.nlm.nih.gov/pubmed/33690265/)\]
### Database Entries (Apr 06)
Thomson EC, Rosen LE, et int., and Snell G. [‚ÄúCirculating SARS-CoV-2 spike N439K variants maintain fitness while evading antibody-mediated immunity.‚Äù](/search/?article=Thomson21) _Cell_, 2021. [doi.org/10.1016/j.cell.2021.01.037](https://doi.org/10.1016/j.cell.2021.01.037). \[[PubMed33621484](https://www.ncbi.nlm.nih.gov/pubmed/33621484/)\] \[[PMC7843029](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7843029/)\]

### [Clinical Trials (Apr 01)](/page/updates/#clinical.trials)
[2 clinical trials from ClinicalTrials.gov and WHO ICTRP were added to the registry of Ongoing and Planned Clinical Trials of Antiviral Compounds.](/clinical-trials/?fromDate=2021-04-01)

### Database Entries (Apr 01)
Hattori S, Higashi-Kuwata N, et int., and Mitsuya H. [‚ÄúA small molecule¬†compound with an indole moiety inhibits the main protease of SARS-CoV-2 and blocks virus replication.‚Äù](/search/?article=Hattori21) _Nature Communications_, 2021. [doi.org/10.1038/s41467-021-20900-6](https://doi.org/10.1038/s41467-021-20900-6). \[[PubMed33510133](https://www.ncbi.nlm.nih.gov/pubmed/33510133/)\] \[[PMC7843602](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7843602/)\]
### Database Entries (Apr 01)
Vatansever EC, Yang KS, et int., and Liu WR. [‚ÄúBepridil is potent against SARS-CoV-2 in vitro.‚Äù](/search/?article=Vatansever21) _Proceedings of the National Academy of Sciences_, 2021. [doi.org/10.1073/pnas.2012201118](https://doi.org/10.1073/pnas.2012201118). \[[PubMed33597253](https://www.ncbi.nlm.nih.gov/pubmed/33597253/)\] \[[PMC7958448](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7958448/)\]
### Database Entries (Mar 31)
Skelly DT, Harding AC, et int., and James WS. [‚ÄúVaccine-induced immunity provides more robust heterotypic immunity than natural infection to emerging SARS-CoV-2 variants of concern.‚Äù](/search/?article=Skelly21) _Research square_, 2021. [doi.org/10.21203/rs.3.rs-226857/v1](https://doi.org/10.21203/rs.3.rs-226857/v1).
### Database Entries (Mar 31)
Zhou H, Dcosta BM, et int., and Tada T. [‚ÄúB.1.526 SARS-CoV-2 variants identified in New York City are neutralized by vaccine-elicited and therapeutic monoclonal antibodies.‚Äù](/search/?article=Zhou21c) _bioRxiv_, 2021. [doi.org/10.1101/2021.03.24.436620](https://doi.org/10.1101/2021.03.24.436620).
### Database Entries (Mar 31)
Zuckerman NS, Fleishon S, et int., and Mor O. [‚ÄúA unique SARS-CoV-2 spike protein P681H strain detected in Israel.‚Äù](/search/?article=Zuckerman21) _medRxiv_, 2021. [doi.org/10.1101/2021.03.25.21253908](https://doi.org/10.1101/2021.03.25.21253908).
### [Clinical Trials (Mar 25)](/page/updates/#clinical.trials)
[2 clinical trials from ClinicalTrials.gov and WHO ICTRP were added to the registry of Ongoing and Planned Clinical Trials of Antiviral Compounds.](/clinical-trials/?fromDate=2021-03-25)
### Database Entries (Mar 23)
Chen RE, Zhang X, et int., and Diamond MS. ‚ÄúResistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies.‚Äù _Nature Medicine_, 2021. [doi.org/10.1038/s41591-021-01294-w](https://doi.org/10.1038/s41591-021-01294-w). \[[PubMed33664494](https://www.ncbi.nlm.nih.gov/pubmed/33664494/)\]
### Database Entries (Mar 23)
Emary KRW, Golubchik T, et int., and Group OCVT. ‚ÄúEfficacy of ChAdOx1 nCoV-19&nbsp;(AZD1222)&nbsp;Vaccine Against SARS-CoV-2 VOC&nbsp;202012/01&nbsp;(B.1.1.7).‚Äù _SSRN Electronic Journal_, 2021. [doi.org/10.2139/ssrn.3779160](https://doi.org/10.2139/ssrn.3779160).
### Database Entries (Mar 23)
Kuzmina A, Khalaila Y, et int., and Taube R. ‚ÄúSARS CoV-2 escape variants exhibit differential infectivity and neutralization sensitivity to convalescent or post-vaccination sera.‚Äù _medRxiv_, 2021. [doi.org/10.1101/2021.02.22.21252002](https://doi.org/10.1101/2021.02.22.21252002).
### Database Entries (Mar 23)
Tang J, Lee Y, et int., and Khurana S. ‚ÄúReduced neutralization of SARS-CoV-2 variants by convalescent plasma and hyperimmune intravenous immunoglobulins for treatment of COVID-19.‚Äù _bioRxiv_, 2021. [doi.org/10.1101/2021.03.19.436183](https://doi.org/10.1101/2021.03.19.436183).
### [Clinical Trials (Mar 18)](/page/updates/#clinical.trials)
[2 clinical trials from ClinicalTrials.gov and WHO ICTRP were added to the registry of Ongoing and Planned Clinical Trials of Antiviral Compounds.](/clinical-trials/?fromDate=2021-03-18)

### Database Entries (Mar 18)
Becker M, Dulovic A, et int., and Schneiderhan-Marra N. [‚ÄúImmune response to SARS-CoV-2 variants of concern in vaccinated individuals.‚Äù](/search/?article=Becker21) _medRxiv_, 2021. [doi.org/10.1101/2021.03.08.21252958](https://doi.org/10.1101/2021.03.08.21252958).
### Database Entries (Mar 18)
Brown JC, Goldhill DH, et int., and Barclay WS. [‚ÄúIncreased transmission of SARS-CoV-2 lineage B.1.1.7 (VOC 2020212/01) is not accounted for by a replicative advantage in primary airway cells or antibody escape.‚Äù](/search/?article=Brown21) _bioRxiv_, 2021. [doi.org/10.1101/2021.02.24.432576](https://doi.org/10.1101/2021.02.24.432576).
### Database Entries (Mar 18)
Dejnirattisai W, Zhou D, et int., and Screaton GR. [‚ÄúAntibody evasion by the Brazilian P.1 strain of SARS-CoV-2.‚Äù](/search/?article=Dejnirattisai21) _bioRxiv_, 2021. [doi.org/10.1101/2021.03.12.435194](https://doi.org/10.1101/2021.03.12.435194).
### Database Entries (Mar 18)
Ku Z, Xie X, et int., and An Z. [‚ÄúMolecular determinants and mechanism for antibody cocktail preventing SARS-CoV-2 escape.‚Äù](/search/?article=Ku21) _Nature Communications_, 2021. [doi.org/10.1038/s41467-020-20789-7](https://doi.org/10.1038/s41467-020-20789-7). \[[PubMed33473140](https://www.ncbi.nlm.nih.gov/pubmed/33473140/)\] \[[PMC7817669](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7817669/)\]
### Database Entries (Mar 18)
Madhi SA, Baillie V, et int., and Izu A. [‚ÄúSafety and efficacy of the ChAdOx1 nCoV-19 (AZD1222) Covid-19 vaccine against the B.1.351 variant in South Africa.‚Äù](/search/?article=Madhi21) _medRxiv_, 2021. [doi.org/10.1101/2021.02.10.21251247](https://doi.org/10.1101/2021.02.10.21251247).
### Database Entries (Mar 18)
Resende PC, Gr√§f T, et int., and Siqueira MM. [‚ÄúA potential SARS-CoV-2 variant of interest (VOI) harboring mutation E484K in the Spike protein was identified within lineage B.1.1.33 circulating in Brazil.‚Äù](/search/?article=Resende21) _bioRxiv_, 2021. [doi.org/10.1101/2021.03.12.434969](https://doi.org/10.1101/2021.03.12.434969).
### Database Entries (Mar 18)
Supasa P, Zhou D, et int., and Screaton GR. [‚ÄúReduced neutralization of SARS-CoV-2 B.1.1.7 variant by convalescent and vaccine sera.‚Äù](/search/?article=Supasa21) _Cell_, 2021. [doi.org/10.1016/j.cell.2021.02.033](https://doi.org/10.1016/j.cell.2021.02.033).
### Database Entries (Mar 18)
Zhou D, Dejnirattisai W, et int., and Screaton GR. [‚ÄúEvidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera.‚Äù](/search/?article=Zhou21b) _Cell_, 2021. [doi.org/10.1016/j.cell.2021.02.037](https://doi.org/10.1016/j.cell.2021.02.037). \[[PubMed33730597](https://www.ncbi.nlm.nih.gov/pubmed/33730597/)\]
### Database Entries (Mar 14)
Cathcart AL, Havenar-Daughton C, et int., and Hebner CM. [‚ÄúThe dual function monoclonal antibodies VIR-7831 and VIR-7832 demonstrate potent in vitro and in vivo activity against SARS-CoV-2.‚Äù](/search/?article=Cathcart21) _bioRxiv_, 2021. [doi.org/10.1101/2021.03.09.434607](https://doi.org/10.1101/2021.03.09.434607).
### Database Entries (Mar 14)
Copin R, Baum A, et int., and Kyratsous CA. [‚ÄúIn vitro and in vivo preclinical studies predict REGEN-COV protection against emergence of viral escape in humans.‚Äù](/search/?article=Copin21) _bioRxiv_, 2021. [doi.org/10.1101/2021.03.10.434834](https://doi.org/10.1101/2021.03.10.434834).
### Database Entries (Mar 14)
Deng X, Garcia-Knight MA, et int., and Chiu CY. [‚ÄúTransmission, infectivity, and antibody neutralization of an emerging SARS-CoV-2 variant in California carrying a L452R spike protein mutation.‚Äù](/search/?article=Deng21) _medRxiv_, 2021. [doi.org/10.1101/2021.03.07.21252647](https://doi.org/10.1101/2021.03.07.21252647).
### Database Entries (Mar 14)
Wang R, Zhang Q, et int., and Zhang L. [‚ÄúSpike mutations in SARS-CoV-2 variants confer resistance to antibody neutralization.‚Äù](/search/?article=Wang21f) _bioRxiv_, 2021. [doi.org/10.1101/2021.03.09.434497](https://doi.org/10.1101/2021.03.09.434497).
### Database Entries (Mar 14)
Widera M, Wilhelm A, et int., and Ciesek S. [‚ÄúBamlanivimab does not neutralize two SARS-CoV-2 variants carrying E484K in vitro.‚Äù](/search/?article=Widera21) _medRxiv_, 2021. [doi.org/10.1101/2021.02.24.21252372](https://doi.org/10.1101/2021.02.24.21252372).
